Accepted Articles
Back to the articles list |
Back to browse issues page
Mahdieh Mehmandoust1 
, Shima Raeesi2 , Rezvan Hashemi2 , Mohammad Bidkhori3 , Alireza Namazi Shabestari1 , Fatemeh Dashti4 , Farzaneh Asoudeh4 , Zahra Vahabi * 5
, Shima Raeesi2 , Rezvan Hashemi2 , Mohammad Bidkhori3 , Alireza Namazi Shabestari1 , Fatemeh Dashti4 , Farzaneh Asoudeh4 , Zahra Vahabi * 5
1- Department of Geriatric Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
2- Department of Geriatric Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
4- Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
5- Memory and Behavioral Neurology Division, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
2- Department of Geriatric Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
4- Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
5- Memory and Behavioral Neurology Division, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:
Background: Dementia is a progressive neurodegenerative disorder and a significant healthcare concern increasing worldwide. The modulation of the gut-brain axis by gut microbiota might have favorable effects on ameliorating cognitive decline. Our objective was to investigate whether synbiotics administration could enhance cognition and function in older adults with non-severe Alzheimer's disease (AD).
Methods: This study was designed as a randomized, placebo-controlled, double-blinded clinical trial to test the effects of synbiotic supplementation for 90 days (Between August 2019 and February 2021). A synbiotics formulation or placebo was randomly allocated to older outpatients with mild to moderate AD. The intervention group took two capsules daily containing the mixture of 7 bacterial strains as probiotics and a prebiotic for 12 weeks. Mini-Mental State Examination (MMSE), and Barthel index evaluated participants' cognition and functional status. Pre- and post-intervention fasting blood samples were obtained to compare the serum albumin, fasting blood sugar (FBS), 25(OH) vitamin D, and lipid profile.
Results: 60 patients (Mean age of 77 years) were recruited. After 12 weeks of synbiotic supplementation, no significant improvement was detected in the MMSE Score (p=0.53) and Barthel index (p=0.43), respectively. Furthermore, metabolic parameters including FBS (p=0.92), triglyceride (P=0.48), total cholesterol (P=0.74), high-density lipoprotein (P=0.54), low-density lipoprotein (P=0.79), serum albumin (p=0.28) and 25(OH) vitamin D levels (p=0.67) were not different before and after synbiotic administration.
Conclusion: This study does not support short-term synbiotic supplementation to enhance cognitive and physical function in elderly patients with mild to moderate AD.
Methods: This study was designed as a randomized, placebo-controlled, double-blinded clinical trial to test the effects of synbiotic supplementation for 90 days (Between August 2019 and February 2021). A synbiotics formulation or placebo was randomly allocated to older outpatients with mild to moderate AD. The intervention group took two capsules daily containing the mixture of 7 bacterial strains as probiotics and a prebiotic for 12 weeks. Mini-Mental State Examination (MMSE), and Barthel index evaluated participants' cognition and functional status. Pre- and post-intervention fasting blood samples were obtained to compare the serum albumin, fasting blood sugar (FBS), 25(OH) vitamin D, and lipid profile.
Results: 60 patients (Mean age of 77 years) were recruited. After 12 weeks of synbiotic supplementation, no significant improvement was detected in the MMSE Score (p=0.53) and Barthel index (p=0.43), respectively. Furthermore, metabolic parameters including FBS (p=0.92), triglyceride (P=0.48), total cholesterol (P=0.74), high-density lipoprotein (P=0.54), low-density lipoprotein (P=0.79), serum albumin (p=0.28) and 25(OH) vitamin D levels (p=0.67) were not different before and after synbiotic administration.
Conclusion: This study does not support short-term synbiotic supplementation to enhance cognitive and physical function in elderly patients with mild to moderate AD.
Keywords: Synbiotics, Cognitive function, Activity of daily living, Elderly, Alzheimer’s disease
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
